President Donald Trump signed an executive order in April 2026 dedicating $50 million in federal funding toward research into the psychedelic drug ibogaine.

Mind-altering substances like psilocybin, LSD, MDMA, and ayahuasca and their therapeutic and cultural use.

First government-funded clinical trials of ibogaine for opioid addiction and PTSD, conducted by the FDA and VA.